Navigation Links
Delcath Reports 2014 Second Quarter Results
Date:8/6/2014

sponsored clinical trials or investigator initiated trials, continued clinical adoption, use and resulting, sales, if any, of the CHEMOSAT system in Europe including the UK and Germany, the Company's ability to successfully commercialize the Melphalan HDS/ CHEMOSAT system and the potential of the Melphalan HDS/CHEMOSAT system as a treatment for patients with primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets, the Company's ability to satisfy the requirements of the FDA's Complete Response Letter and provide the same in a timely manner, approval of the current or future Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the US and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, the Company's ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same, uncertainties relating to the timing and results of research and development projects, and uncertainties regarding the Company's ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.Contact Information:Investor Contact:

Media Contact:Michael Polyviou/Doug Sherk

John CarterEVC Group

EVC Group212-850-6020

212-850-6021 Delcath Systems, Inc.Condensed Consolidated Statements of Operations and Comprehensive Lossfor the three and six months ended Ju
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Delcath Systems, Inc. Secures $20 Million Credit Facility
2. Delcath Highlights First Quarter 2012 And Recent Accomplishments
3. Delcath to Webcast Managements Presentation at Annual Meeting of Stockholders
4. Delcath Prices $20 Million Public Offering of Common Stock and Warrants
5. Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
6. Delcath Announced Changes To Board Of Directors
7. Delcath To Present At JMP Securities Healthcare Conference On July 12
8. Delcath To Conduct Second Quarter 2012 Results Conference Call
9. Delcath Reports Second Quarter 2012 Financial Results And Highlights Recent Accomplishments
10. Delcath To Present At Upcoming Investor Conferences
11. Delcath Submits New Drug Application For Proprietary Chemosaturation System To The U.S. Food And Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 PuraMed BioScience®, Inc., (OTC Pink: ... medicinal and healthcare products, announced it received the initial ... hemp-based, advanced headache relief product, for planned distribution to ... Colorado , Washington State , ... the MigraPure H Advanced headache relief gel formulation completed, ...
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
(Date:12/24/2014)... Calif. , Dec. 23, 2014 In response ... Doctors, Association of Sierra Leone , Direct ... Leone for the treatment of local health workers ... While a new dedicated Ebola care center was constructed for ... the facility is not available for local Sierra Leonean health ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... RAD001 reduces risk of disease progression by 70%, - RAD001 is first and ... Nexavar(R),** with potential to address ... unmet medical need,- Once-daily oral RAD001 directly targets ... and blood vessel growth, - RAD001 is currently being studied in multiple types ...
... Adding Singulair to Advair Offers no Additional ... Improvement in Overall Asthma ... 18 /PRNewswire-FirstCall/,-- Patients with both asthma and allergic rhinitis, ... with Advair,Diskus(R) (fluticasone propionate and salmeterol inhalation powder) as,compared ...
Cached Medicine Technology:RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 2RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 3RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 4RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 5RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 6Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM) 2Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM) 3
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses and ... of black one-shoulder cocktail dresses . In addition, all ... at discounted prices, up to 70% off. , ... weeks only. You know, we have thousands of frequent callers ... new items can visit our website for more details. The ...
(Date:12/25/2014)... 25, 2014 BambooFlooringChina.com sells many bamboo ... bamboo flooring. Today, the company announces big discounts ... styles and colors. , BambooFlooringChina.com is the world’s leader ... promotion is valid until Jan. 20, 2015. , The ... woven with a natural thread. All the bamboo strips ...
(Date:12/25/2014)... By Dennis Thompson ... -- Very sick children with complex chronic illnesses can receive ... a "medical home," with easy access to a team of ... were less likely to become seriously ill and need either ... received treatment at an enhanced medical home clinic at the ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... closing in on a "fountain of youth" drug that can ... older adults, a new study suggests. Seniors received a ... that targets a genetic signaling pathway linked to aging and ... The experimental medication, a version of the drug ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios have ... business presentation tool made specifically for Final Cut ... tool, users can now display their stats and facts ... Studios. “ProFire 5k gives users a multiple options to ... a presentation” , Pixel Film Studios takes the heat ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... YORK, Feb 26 Our faces are our calling ... and are connected with three out of the five ... what happens when what you see in the mirror ... News Release, go to: http://www.prnewswire.com/mnr/aafprs/35820/ If you have ...
... 26 Solos Endoscopy, Inc. (Pink Sheets: SNDY) is ... significant purchase order for the MammoView(TM) line of surgical ... Waterbury Hospital, the cornerstone of the Greater Waterbury Health ... care services since 1983 and is accredited by the ...
... Pharma, Inc.,(Nasdaq: IDMI ) today announced that ... and more than 100 patient organizations, caregivers,researchers and companies ... on February 28. The goal of the day ... by those affected and the importance,of research to develop ...
... (Nasdaq: STRM ) announced today that Jay ... of Directors. The addition of Mr. Miller brings to ... Health Board of Directors.Mr. Miller has spent roughly 25 ... development; sales and marketing; and profit and loss responsibilities. ...
... - Quarter Highlighted by Regulatory Approval of Once-Daily Tramadol in, ... for Novel Treatment for Depression -,LAVAL, QC, Feb. 26 /PRNewswire-FirstCall/ ... today reported its results for the fourth quarter and year ... unless otherwise stated. , "With our first product about to ...
... To Autism" and Provides Important Information on Early ... Toys"R"Us and Babies"R"Us stores nationwide will kick off ... Speaks, the nation,s leading organization dedicated to increasing ... the causes, prevention and treatments for autism; and ...
Cached Medicine News:Health News:Video: Facing the Facts - What You Need to Know About Facial Plastic Surgery 2Health News:Solos Endoscopy, Inc. Receives Purchase Order from Major Connecticut Hospital for the MammoView(TM) 2Health News:IDM Pharma Joins NORD to Raise Awareness of Rare Diseases 2Health News:IDM Pharma Joins NORD to Raise Awareness of Rare Diseases 3Health News:IDM Pharma Joins NORD to Raise Awareness of Rare Diseases 4Health News:Streamline Health Appoints Jay D. Miller to Board of Directors 2Health News:Streamline Health Appoints Jay D. Miller to Board of Directors 3Health News:Streamline Health Appoints Jay D. Miller to Board of Directors 4Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 2Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 3Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 4Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 5Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 6Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 7Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 8Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 9Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 10Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 11Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 12Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 13Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 14Health News:Toys'R'Us and Babies'R'Us Launch In-Store Fundraising Campaign to Benefit Autism Speaks 2Health News:Toys'R'Us and Babies'R'Us Launch In-Store Fundraising Campaign to Benefit Autism Speaks 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: